- News & Media
Tikcro is pursuing the discovery and pre-clinical development of product candidates leveraging license agreements with Israeli academic research centers. A collaboration with the Weizmann Institute of Science in Israel resulted with promising potential therapuetic antibodies for the treatment of cancer. Leveraging unique antigen design technology for the generation of antibodies, this approach shows early success in the following pipeline. Going forward, in 2017 we plan to promote early-stage candidates which we first validate into rigorous pre clinical trials and aim to build sufficient data for further progress and clinical trials.
We are currently focused on antibody drug-candidates for the stimulation of self immune system in combating cancer diseases. We expect our product candidate antibodies to block the ligand/receptor linkage of certain biological pathways, specifically antibodies that block CTLA-4, PD1 and TIGIT, and by blocking these pathways to prevent the inhibition of patients’ self immune system and its ability to attack cancerous cells. This prevention is known to have positive clinical effects and to extend overall survival.